Abstract 1105: Cisplatin treatment alters the preference of melanoma metastasis to liver associated with Ly6G positive cells

Abstract

Abstract This study examined the influence of cisplatin on host stroma and its consequence on metastasis using a metastatic melanoma tumor model. This preliminary result indicates that Gr-1+ cells could play important role on cisplatin treatment-directed liver metastasis. To further examine the role of Gr-1+ cells on this phenomena, Gr-1Ab was administered at day 16 after tumor inoculation. Results show that Gr-1Ab treatment could effectively decrease the Ly6G+ cells in both lung and liver and without significant reduced in lung-metastasis but, increased the metastasis in lung. To identify the effect of cisplatin treatment on B16-F0 melanoma metastasis, normal mice were treated with cisplatin prior to iv inject of B16-F0 melanoma cells. Cisplatin prevented treatment, similar to Gr-1 Ab therapy, decreased Ly6G+ cell in lung and liver tissue. And, it is minor difference of lung metastasis compare to Gr-1 Ab treatment, but more metastatic site than it. It demonstrates that cisplatin therapy induced liver-metastasis could associate with Ly6G+ cells. This study concludes that the cisplatin treatment could alter the preference of tumor metastasis, which is associated with the reduction of Ly6G+ cells It could be a potential target to enhance therapy efficiency. Citation Format: Chang Chun-Hsiang. Cisplatin treatment alters the preference of melanoma metastasis to liver associated with Ly6G positive cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1105.